Your browser doesn't support javascript.
loading
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh, Aparna R; Van Seventer, Emily E; Siravegna, Giulia; Hartwig, Anna V; Jaimovich, Ariel; He, Yupeng; Kanter, Katie; Fish, Madeleine G; Fosbenner, Kathryn D; Miao, Benchun; Phillips, Susannah; Carmichael, John H; Sharma, Nihaarika; Jarnagin, Joy; Baiev, Islam; Shah, Yojan S; Fetter, Isobel J; Shahzade, Heather A; Allen, Jill N; Blaszkowsky, Lawrence S; Clark, Jeffrey W; Dubois, Jon S; Franses, Joseph W; Giantonio, Bruce J; Goyal, Lipika; Klempner, Samuel J; Nipp, Ryan D; Roeland, Eric J; Ryan, David P; Weekes, Colin D; Wo, Jennifer Y; Hong, Theodore S; Bordeianou, Liliana; Ferrone, Cristina R; Qadan, Motaz; Kunitake, Hiroko; Berger, David; Ricciardi, Rocco; Cusack, James C; Raymond, Victoria M; Talasaz, AmirAli; Boland, Genevieve M; Corcoran, Ryan B.
Afiliação
  • Parikh AR; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Van Seventer EE; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Siravegna G; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Hartwig AV; Guardant Health, Inc, Redwood City, California.
  • Jaimovich A; Guardant Health, Inc, Redwood City, California.
  • He Y; Guardant Health, Inc, Redwood City, California.
  • Kanter K; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Fish MG; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Fosbenner KD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Miao B; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Phillips S; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Carmichael JH; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Sharma N; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Jarnagin J; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Baiev I; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Shah YS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Fetter IJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Shahzade HA; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Allen JN; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Blaszkowsky LS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Clark JW; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Dubois JS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Franses JW; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Giantonio BJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Goyal L; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Klempner SJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Nipp RD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Roeland EJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Ryan DP; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Weekes CD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Wo JY; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
  • Bordeianou L; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.
  • Ferrone CR; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.
  • Qadan M; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Kunitake H; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.
  • Berger D; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.
  • Ricciardi R; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.
  • Cusack JC; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Raymond VM; Guardant Health, Inc, Redwood City, California.
  • Talasaz A; Guardant Health, Inc, Redwood City, California.
  • Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Corcoran RB; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. rbcorcoran@partners.org.
Clin Cancer Res ; 27(20): 5586-5594, 2021 10 15.
Article em En | MEDLINE | ID: mdl-33926918
PURPOSE: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection. EXPERIMENTAL DESIGN: A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. RESULTS: Of 103 patients, 84 [stage I (9.5%), II (23.8%), III (47.6%), IV (19%)] had evaluable plasma drawn after completion of definitive therapy, defined as surgery only (n = 39) or completion of adjuvant therapy (n = 45). In "landmark" plasma drawn 1-month (median, 31.5 days) after definitive therapy and >1 year follow-up, 15 patients had detectable ctDNA, and all 15 recurred [positive predictive value (PPV), 100%; HR, 11.28 (P < 0.0001)]. Of 49 patients without detectable ctDNA at the landmark timepoint, 12 (24.5%) recurred. Landmark recurrence sensitivity and specificity were 55.6% and 100%. Incorporating serial longitudinal and surveillance (drawn within 4 months of recurrence) samples, sensitivity improved to 69% and 91%. Integrating epigenomic signatures increased sensitivity by 25%-36% versus genomic alterations alone. Notably, standard serum carcinoembryonic antigen levels did not predict recurrence [HR, 1.84 (P = 0.18); PPV = 53.9%]. CONCLUSIONS: Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection.See related commentary by Bent and Kopetz, p. 5449.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasia Residual / DNA Tumoral Circulante Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasia Residual / DNA Tumoral Circulante Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos